Leukemia
Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia
Telzerow E, Görlich D, Sauerland C, et al
In this questionnaire-based, cross-sectional study, 427 former AML patients participated ≥5 years and up to 18.6 years past their leukemia diagnosis. The authors identified factors associated with impaired outcomes (e.g., comorbidity and fatigue), delineating a subgroup of survivors with unmet needs ≥5 years after their AML diagnosis.
Previous Article
- • Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study
- • Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML
- • Quality of life and life satisfaction in long-term survivors of acute myeloid leukemia
- • Integrative genomic and immune profiling to identify and characterize high-risk subgroups in AML: development of a 20-gene predictive signature
- • Targeting p16INK4a-mediated cellular senescence as a therapeutic strategy for FLT3-ITD-driven AML
- • Gilteritinib in FLT3-mutated AML: a real-world Italian experience
- • Decitabine combined with reduced-intensity conditioning for older patients with AML in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation
- • Prognostic covariates associated with outcomes in patients with NPM1-mutated AML
- • Venetoclax combined with azacitidine in elderly AML
- • Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory AML
- • Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML
- • Bexmarilimab plus azacitidine for high-risk MDS and relapsed or refractory AML
- • Comparison of consolidation strategies for pediatric patients with AML
- • Molecular monitoring versus standard clinical care in younger adults with AML
- • A phase 2 trial of geriatric assessment-guided selection of treatment intensity in older adults with AML
